Immune cell therapy takes on lupus in early trial
NCT ID NCT06518668
First seen Apr 23, 2026 · Last updated Jun 11, 2026 · Updated 8 times
Summary
This early-phase study tests a new treatment called NKX019 for people with systemic lupus erythematosus (SLE), an autoimmune disease. NKX019 uses specially engineered immune cells to target and destroy faulty B cells that drive the disease. The main goal is to check safety and tolerability in up to 6 adults, while also looking for signs of clinical improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.